Joe Rogan Experience #2568 - Ross Edgley · Aired Oct 20, 2026
Claim summary · not a verbatim quotation
Muse stem cells are a recent and highly effective innovation in stem cell therapy.
The finding
What remains unresolved
Joe calls Muse cells one of the greatest recent innovations, then says more studies are needed. A small placebo-controlled trial of CL2020 in subacute stroke is promising but does not establish the effectiveness of commercial Muse-cell treatment for a rotator cuff or general recovery. The superlative is opinion and the broad treatment claim remains unresolved; nonapproval alone would not disprove efficacy.
Read the supporting source · pmc.ncbi.nlm.nih.gov ↗Quick answer & review status
Quick answer
Is it true that Muse stem cells are a recent and highly effective innovation in stem cell therapy?
We can't say yet. Joe calls Muse cells one of the greatest recent innovations, then says more studies are needed. A small placebo-controlled trial of CL2020 in subacute stroke is promising but does not establish the effectiveness of commercial Muse-cell treatment for a rotator cuff or general recovery. Joe Rogan said it (matched by voice) on Joe Rogan Experience #2568 - Ross Edgley, aired Oct 20, 2026, at 2:38:05. We couldn't settle it from the evidence we captured, so it stays an open question, not a false claim. The supporting source is pmc.ncbi.nlm.nih.gov, linked below.
The context belongs here.
No separately verified on-air correction is recorded for this check. That is not a claim that nobody corrected it.
- Attribution
- Not independently confirmed in this record
- Editorial context review
- Not recorded; generated finding
- Coverage
- One selected claim from the episode
Revisions to this check
No dated revision is recorded here. Older checks may predate this log.
Challenge this finding or add context →Keep the evidence coming.
Follow new checks in your RSS reader, or catch up with the weekly briefing on the site.
Email signup is currently unavailable.
Prefer to catch up here? Read the weekly briefing.